NRIX

Nurix Therapeutics, Inc.

Price Chart

No historical data available

Latest Quote

$25.30

-0.91 (-3.47%)

Current Price

Previous Close	$26.21
Open	$26.00
Day High	$26.23
Day Low	$25.17
Volume	419,575

Fetched: 2026-08-31T18:27:42

Stock Information

Shares Outstanding	103.78M
Total Debt	$58.14M
Cash Equivalents	$443.53M
Revenue	$36.77M
Net Income	$-341.35M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.63B
EPS (TTM)	$-3.46
Exchange	NGM

🌐 Visit Website

Recent Price History

No history data available. Data will be fetched automatically.

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

📰 Latest News

No news articles available at the moment. Check back later for updates on NRIX.

Period:

Income Statement (Annual)

Metric	2025-11-30	2024-11-30	2023-11-30	2022-11-30
Revenue
Total Revenue	$83,980,000	$54,549,000	$76,987,000	$38,627,000
Operating Revenue	$83,980,000	$54,549,000	$76,987,000	$38,627,000
Expenses
Total Expenses	$369,646,000	$267,576,000	$232,050,000	$222,494,000
Net Non Operating Interest Income Expense	$21,969,000	$19,728,000	$11,115,000	$3,507,000
Operating Expense	$369,646,000	$267,576,000	$232,050,000	$222,494,000
General And Administrative Expense	$52,743,000	$45,944,000	$42,902,000	$37,997,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Net Interest Income	$21,969,000	$19,728,000	$11,115,000	$3,507,000
Interest Income	$21,969,000	$19,728,000	$11,115,000	$3,507,000
Normalized Income	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Net Income From Continuing And Discontinued Operation	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Total Operating Income As Reported	$-285,666,000	$-213,027,000	$-155,063,000	$-183,867,000
Net Income Common Stockholders	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Net Income	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Net Income Including Noncontrolling Interests	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Net Income Continuous Operations	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Pretax Income	$-263,697,000	$-193,299,000	$-143,948,000	$-180,360,000
Interest Income Non Operating	$21,969,000	$19,728,000	$11,115,000	$3,507,000
Operating Income	$-285,666,000	$-213,027,000	$-155,063,000	$-183,867,000
Per Share
Diluted EPS	$-3.05	$-2.88	$-2.65	$-3.71
Basic EPS	$-3.05	$-2.88	$-2.65	$-3.71
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-266,810,000	$-196,599,000	$-141,409,000	$-173,059,000
Reconciled Depreciation	$18,856,000	$16,428,000	$13,654,000	$10,808,000
EBITDA (Bullshit earnings)	$-266,810,000	$-196,599,000	$-141,409,000	$-173,059,000
EBIT	$-285,666,000	$-213,027,000	$-155,063,000	$-183,867,000
Diluted Average Shares	$86,666,907	$67,120,266	$54,337,901	$48,607,990
Basic Average Shares	$86,666,907	$67,120,266	$54,337,901	$48,607,990
Diluted NI Availto Com Stockholders	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Tax Provision	$760,000	$270,000	$0	$0
Research And Development	$316,903,000	$221,632,000	$189,148,000	$184,497,000
Selling General And Administration	$52,743,000	$45,944,000	$42,902,000	$37,997,000
Other Gand A	$52,743,000	$45,944,000	$42,902,000	$37,997,000

Fetched: 2026-08-25

Balance Sheet (Annual)

Metric	2025-11-30	2024-11-30	2023-11-30	2022-11-30
Assets
Net Tangible Assets	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Total Assets	$688,135,000	$669,343,000	$355,598,000	$416,759,000
Total Non Current Assets	$81,316,000	$49,956,000	$60,095,000	$98,310,000
Other Non Current Assets	$8,309,000	$4,060,000	$4,724,000	$4,923,000
Current Assets	$606,819,000	$619,387,000	$295,503,000	$318,449,000
Other Current Assets	$13,878,000	$9,804,000	$7,595,000	$9,308,000
Cash Cash Equivalents And Short Term Investments	$592,941,000	$609,583,000	$287,908,000	$309,141,000
Cash And Cash Equivalents	$246,960,000	$109,997,000	$54,627,000	$64,474,000
Investmentin Financial Assets	-	$0	$7,421,000	$63,879,000
Receivables	-	-	-	$0
Taxes Receivable	-	-	-	$0
Accounts Receivable	-	-	-	$0
Prepaid Assets	-	-	-	-
Debt
Total Debt	$55,730,000	$28,303,000	$30,614,000	$11,964,000
Long Term Debt And Capital Lease Obligation	$52,906,000	$20,289,000	$23,125,000	$6,434,000
Current Debt And Capital Lease Obligation	$2,824,000	$8,014,000	$7,489,000	$5,530,000
Liabilities
Total Liabilities Net Minority Interest	$149,388,000	$142,350,000	$155,105,000	$113,063,000
Total Non Current Liabilities Net Minority Interest	$62,917,000	$46,496,000	$68,147,000	$42,408,000
Non Current Deferred Liabilities	$10,011,000	$26,207,000	$45,022,000	$35,974,000
Current Liabilities	$86,471,000	$95,854,000	$86,958,000	$70,655,000
Other Current Liabilities	$2,096,000	$2,275,000	$751,000	$1,503,000
Current Deferred Liabilities	$17,580,000	$38,364,000	$48,098,000	$37,633,000
Payables And Accrued Expenses	$42,430,000	$30,570,000	$15,317,000	$12,825,000
Payables	$12,274,000	$12,719,000	$6,431,000	$5,149,000
Total Tax Payable	$1,059,000	$1,237,000	$30,000	$85,000
Accounts Payable	$11,215,000	$11,482,000	$6,401,000	$5,064,000
Equity
Common Stock Equity	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Total Equity Gross Minority Interest	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Stockholders Equity	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Gains Losses Not Affecting Retained Earnings	$105,000	$150,000	$-655,000	$-4,319,000
Other Equity Adjustments	$105,000	$150,000	$-655,000	$-4,319,000
Retained Earnings	$-1,003,226,000	$-738,769,000	$-545,200,000	$-401,252,000
Other
Ordinary Shares Number	$101,807,484	$75,870,718	$48,718,552	$47,172,299
Share Issued	$101,807,484	$75,870,718	$48,718,552	$47,172,299
Tangible Book Value	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Invested Capital	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Working Capital	$520,348,000	$523,533,000	$208,545,000	$247,794,000
Capital Lease Obligations	$55,730,000	$28,303,000	$30,614,000	$11,964,000
Total Capitalization	$538,747,000	$526,993,000	$200,493,000	$303,696,000
Additional Paid In Capital	$1,541,766,000	$1,265,536,000	$746,299,000	$709,220,000
Capital Stock	$102,000	$76,000	$49,000	$47,000
Common Stock	$102,000	$76,000	$49,000	$47,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$10,011,000	$26,207,000	$45,022,000	$35,974,000
Long Term Capital Lease Obligation	$52,906,000	$20,289,000	$23,125,000	$6,434,000
Current Deferred Revenue	$17,580,000	$38,364,000	$48,098,000	$37,633,000
Current Capital Lease Obligation	$2,824,000	$8,014,000	$7,489,000	$5,530,000
Pensionand Other Post Retirement Benefit Plans Current	$21,541,000	$16,631,000	$15,303,000	$13,164,000
Current Accrued Expenses	$30,156,000	$17,851,000	$8,886,000	$7,676,000
Net PPE	$73,007,000	$45,896,000	$47,950,000	$29,508,000
Accumulated Depreciation	$-37,782,000	$-34,502,000	$-26,249,000	$-19,670,000
Gross PPE	$110,789,000	$80,398,000	$74,199,000	$49,178,000
Leases	$9,369,000	$5,140,000	$3,238,000	$3,825,000
Construction In Progress	$141,000	$497,000	$587,000	$697,000
Other Properties	$94,090,000	$67,170,000	$63,381,000	$38,730,000
Machinery Furniture Equipment	$7,189,000	$7,591,000	$6,993,000	$5,926,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$345,981,000	$499,586,000	$233,281,000	$244,667,000
Investments And Advances	-	$0	$7,421,000	$63,879,000
Available For Sale Securities	-	-	$7,421,000	$63,879,000

Fetched: 2026-08-25

Cash Flow Statement (Annual)

Metric	2025-11-30	2024-11-30	2023-11-30	2022-11-30
Free Cash Flow
Free Cash Flow	$-263,467,000	$-181,857,000	$-89,766,000	$-172,051,000
Operating Activities
Operating Cash Flow	$-249,465,000	$-172,584,000	$-81,365,000	$-159,807,000
Cash Flow From Continuing Operating Activities	$-249,465,000	$-172,584,000	$-81,365,000	$-159,807,000
Operating Gains Losses	$89,000	$31,000	$556,000	$9,000
Investing Activities
Capital Expenditure	$-14,002,000	$-9,273,000	$-8,401,000	$-12,244,000
Investing Cash Flow	$147,853,000	$-257,713,000	$68,301,000	$27,198,000
Cash Flow From Continuing Investing Activities	$147,853,000	$-257,713,000	$68,301,000	$27,198,000
Financing Activities
Issuance Of Capital Stock	$234,762,000	$478,495,000	$0	$114,159,000
Financing Cash Flow	$238,642,000	$485,667,000	$3,217,000	$117,192,000
Cash Flow From Continuing Financing Activities	$238,642,000	$485,667,000	$3,217,000	$117,192,000
Net Common Stock Issuance	$234,762,000	$478,495,000	$0	$114,159,000
Common Stock Issuance	$234,762,000	$478,495,000	$0	$114,159,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
End Cash Position	$247,928,000	$110,898,000	$55,528,000	$65,375,000
Beginning Cash Position	$110,898,000	$55,528,000	$65,375,000	$80,792,000
Changes In Cash	$137,030,000	$55,370,000	$-9,847,000	$-15,417,000
Proceeds From Stock Option Exercised	$3,880,000	$7,172,000	$3,217,000	$3,033,000
Net Investment Purchase And Sale	$161,855,000	$-248,440,000	$76,702,000	$39,442,000
Sale Of Investment	$617,543,000	$459,513,000	$323,036,000	$278,808,000
Purchase Of Investment	$-455,688,000	$-707,953,000	$-246,334,000	$-239,366,000
Net PPE Purchase And Sale	$-14,002,000	$-9,273,000	$-8,401,000	$-12,244,000
Purchase Of PPE	$-14,002,000	$-9,273,000	$-8,401,000	$-12,244,000
Change In Working Capital	$-31,596,000	$-18,401,000	$20,121,000	$-19,022,000
Change In Other Working Capital	$-36,980,000	$-28,549,000	$19,513,000	$-26,627,000
Change In Other Current Liabilities	$-5,067,000	$-6,418,000	$-6,268,000	$-4,871,000
Change In Payables And Accrued Expense	$16,680,000	$17,025,000	$4,737,000	$7,570,000
Change In Accrued Expense	$17,310,000	$11,816,000	$3,123,000	$7,485,000
Change In Payable	$-630,000	$5,209,000	$1,614,000	$85,000
Change In Account Payable	$-630,000	$5,209,000	$1,614,000	$85,000
Change In Prepaid Assets	$-6,229,000	$-459,000	$2,139,000	$-1,094,000
Stock Based Compensation	$37,965,000	$33,929,000	$33,673,000	$28,131,000
Amortization Of Securities	$-10,322,000	$-11,288,000	$-5,421,000	$426,000
Depreciation Amortization Depletion	$18,856,000	$16,428,000	$13,654,000	$10,808,000
Depreciation And Amortization	$18,856,000	$16,428,000	$13,654,000	$10,808,000
Depreciation	$18,856,000	$16,428,000	$13,654,000	$10,808,000
Gain Loss On Sale Of PPE	$89,000	$31,000	$556,000	$9,000
Net Income From Continuing Operations	$-264,457,000	$-193,569,000	$-143,948,000	$-180,360,000
Change In Receivables	-	$0	$0	$6,000,000
Changes In Account Receivables	-	$0	$0	$6,000,000
Other Non Cash Items	-	$286,000	-	$201,000
Income Tax Paid Supplemental Data	-	-	-	$0

Fetched: 2026-08-25